Skip to main content
Niagen Bioscience, Inc. logo

Niagen Bioscience, Inc. — Investor Relations & Filings

Ticker · NAGE ISIN · US1710774076 LEI · 529900OPI7B8JPXCVS70 US Manufacturing
Open in API
Filings indexed 954 across all filing types
Latest filing 2026-05-06 Regulatory Filings
Country US United States of America
Listing US NAGE

About Niagen Bioscience, Inc.

https://www.niagenbioscience.com/

Niagen Bioscience, Inc. (formerly ChromaDex) is a bioscience company focused on the science of nicotinamide adenine dinucleotide (NAD+). The company aims to improve healthspan and support healthy aging by developing products that restore and optimize cellular NAD+ levels. Its core proprietary ingredient is Niagen®, a patented and clinically studied form of nicotinamide riboside (NR), a precursor to NAD+. Niagen® is the key component in the company's consumer dietary supplement brand, Tru Niagen®, and is also developed for the food, beverage, and pharmaceutical markets. The company's research is supported by numerous human clinical studies, a portfolio of over 50 owned and licensed patents, and collaborations with global research institutions.

Recent filings

Filing Released Lang Actions
8-K - Niagen Bioscience, Inc. (0001386570) (Filer)
Regulatory Filings
2026-05-06 English
8-K - Niagen Bioscience, Inc. (0001386570) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 19, 2026. It announces an increase in the authorization under the company's share repurchase program from $10 million to $20 million. The content focuses on the share repurchase program details, including the amount repurchased so far, the Board's approval, and the terms of the program. There are no financial statements or comprehensive financial data presented, only an announcement of a capital activity. This fits the definition of a Capital/Financing Update (CAP) as it relates to changes in the company's capital structure and financing activities. The document length is 4881 characters, which is sufficient to provide substantive information about the share repurchase program rather than a brief notice. Therefore, the appropriate classification is CAP with high confidence.
2026-03-19 English
8-K - NIAGEN BIOSCIENCE, INC. (0001386570) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 24, 2026. It announces the sale of a business segment (analytical reference standards and services) and includes details about the asset purchase agreement and related transition services. The document is a regulatory announcement of a material event rather than a full financial report or earnings release. It does not contain comprehensive financial statements or detailed financial analysis. The document length is 4735 characters, which is relatively short and consistent with a regulatory announcement. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2026-02-26 English
4 - NIAGEN BIOSCIENCE, INC. (0001386570) (Filer)
Director's Dealing
2026-02-24 English
4 - NIAGEN BIOSCIENCE, INC. (0001386570) (Filer)
Director's Dealing
2026-02-24 English
4 - NIAGEN BIOSCIENCE, INC. (0001386570) (Filer)
Director's Dealing
2026-02-24 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.